USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions
USPSTF recommends against hormone therapy for primary prevention of chronic conditions in postmenopausal persons
USPSTF recommends against hormone therapy for primary prevention of chronic conditions in postmenopausal persons
Nighttime hot flashes, insomnia severity both down at four weeks versus placebo
Longer duration of oral contraceptive use, certain types of tubal ligation associated with lower levels of antimüllerian hormone
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
No associations observed in large study of middle-aged, postmenopausal Korean women
Risk for dementia decreased for cases and controls younger than 80 years who had been taking estrogen-only therapy for 10 years or more
Survey reveals that some women believe cannabis helps with symptoms that overlap with menopause, such as sleep issues and anxiety
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.